Rentokil Initial PLC /FI 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NYSE
Rentokil Initial reports a 4.4% revenue increase to $6.91 billion in 2025, but statutory profit declined, while strategic initiatives in North America show improving organic growth.
NYSE
20-F: Rentokil Initial PLC Releases 20-F Filing, Highlights Strategic Priorities and Financial Performance
Rentokil Initial PLC's 20-F filing highlights the company's strategic priorities, financial performance, and risk management for the fiscal year ended December 31, 2024.
NYSE
20-F: Rentokil Initial PLC Releases 20-F Filing: Details 2023 Financial Performance and Strategic Outlook
Rentokil Initial's 20-F filing highlights the company's 2023 financial results, strategic priorities, and risk factors, emphasizing the integration of Terminix and future growth plans.
NYSE
20-F/A: Rentokil Initial PLC Amends 20-F Filing, Corrects Exhibits and Revises Financial Disclosures
Rentokil Initial PLC has amended its 20-F filing to correct exhibits, revise financial statement disclosures, and remove non-IFRS financial measures.